The Quarterly Review of Economics and Finance
•
2019

Institutional investors and medical innovation

Omer Unsal, Blake Rayfield

Corporate Governance
Innovation

Research Overview

In this research paper, we investigate if institutional investors influence corporate innovation in the US pharmaceutical industry. We hand collect unique datasets from the Food and Drug Administration (FDA), including drug patents, drug approvals, medical device approvals, and Phase I-II-III drugs under clinical testing. We find that higher institutional ownership has a positive, causal effect on firm innovation. We document that institutional ownership increases the number of FDA approved products.

Plain-English Summary

Institutional investors can influence innovation in the pharmaceutical industry, where medical products require long and uncertain development cycles. The study finds a positive relationship between institutional ownership and medical innovation.